# SkinHealth Systems Inc.


**SKIN**

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001818093

# D/E

**on the D/E boundary of 370 graded peers in healthcare**

rank 305 of 370; percentile 82.4; sampling error 2.5 points; lower is stronger





**D/E, the sloth**




| Scoreboard | |
|---|---|
| **Profitability** | C<br>percentile 56.1 |
| **Solvency** | C/D<br>percentile 60.9 |
| **Growth and financing** | D<br>percentile 66.4 |
| **Reliability** | 0.87 AUC<br>filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| **Peer failure rate** | 1.03% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $120M to $591M assets<br>total assets $499.8M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none triggered<br>not computable: short runway, distress, fortress balance sheet |
| **Inputs computable** | 8 of 14 |
| **Graded from** | filings received through Mar 12, 2026<br>224 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026 |
| **Last close** | $10.94<br>2026-10-21; market equity $1.4B; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 12, 2026*

The Beauty Health Company (the "Company" or "we") is a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions designed to help consumers achieve superior skin health and support the success of providers. Anchored by Hydrafacial, a leading and widely requested professional skincare treatment, and supported by complementary offerings including SkinStylus microneedling and HydraScalp powered by Keravive, the Company combines advanced device technology, proprietary consumables, and clinical validation to deliver trusted treatment experiences through an omnichannel network of providers worldwide.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*


| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 56.1** | | | | | | |
| Gross profitability | 39.3% | 32.3% | | 34.1 | 368 | 2025-12-31 |
| Return on invested capital | not computable | 9.3% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| *one or more required annual facts are missing* | | | | | | |
| Accruals ratio | (7.9%) | (6.6%) | 49.1 | 809 | 2025-12-31 | |
| Gross margin stability, five years | 11.3 pts | 2.8 pts | 85.1 | 242 | 2025-12-31 | |
| **Solvency, sleeve percentile 60.9** | | | | | | |
| Twelve-month failure probability | not computable | 0.07% | | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | | |
| Altman Z double-prime | (1.89) | (0.33) | 44.6 | 754 | 2025-12-31 | |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Current ratio | 1.66x | 2.94x | 77.3 | 837 | 2025-12-31 | |
| **Growth and financing, sleeve percentile 66.4** | | | | | | |
| Revenue growth, three-year compound | (6.3%) | 10.1% | 82.0 | 413 | 2025-12-31 | |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *pretax income must exceed the validity floor and imply a 0%-100% tax rate* | | | | | | |
| Asset growth, three years | (20.7%) | 2.1% | 84.8 | 703 | 2025-12-31 | |
| Net share issuance, one year | 2.0% | 2.5% | 32.5 | 634 | 2026-03-09 | |

## Among 370 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 300 | C4 Therapeutics, Inc. (CCCC) | 81.0 | D/E | dilution, fortress balance sheet |
| 301 | Surgery Partners, Inc. (SGRY) | 81.3 | D/E | late filer |
| 302 | Hyperfine, Inc. (HYPR) | 81.6 | D/E | |
| 303 | Accuray Inc. (ARAY) | 81.8 | D/E | late filer |
| 304 | Moderna, Inc. (MRNA) | 82.1 | D/E | |
| 305 | SkinHealth Systems Inc. (SKIN) | 82.4 | D/E | |
| 306 | Karyopharm Therapeutics Inc. (KPTI) | 82.7 | E | dilution, distress, fortress balance sheet |
| 307 | Novavax Inc. (NVAX) | 82.9 | E | |
| 308 | Stereotaxis, Inc. (STXS) | 83.2 | E | |
| 309 | Pyxis Oncology, Inc. (PYXS) | 83.5 | E | short runway, distress |
| 310 | Opko Health, Inc. (OPK) | 83.7 | E | fortress balance sheet |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

## What the price implies

*at the 2026-10-21 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (66.0%) | 7.7% | 8 |
| Distance from 52-week high | (12.5%) | (30.1%) | 73 |
| EBIT to enterprise value | (1.6%) | (1.6%) | 50 |
| Free cash flow yield | 2.6% | (1.0%) | 68 |
| Book value to price | 0.04 | 0.28 | 18 |
| Sales to price | 0.21 | 0.31 | 41 |
| Composite equity issuance, five years | not computable | 20.5% | |
| Relative strength against the sector, log excess return | (1.29) | (0.14) | 8 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | pass |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | pass |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | n/a |
| Operating cash flow, four quarters | n/a |
| Months of runway | not finite |
| Days since last periodic filing | 77 (10-Q received Aug 6, 2026) |
| Median daily dollar volume, 63 sessions | $252,334 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | gross profit | us-gaap:GrossProfit | $196.4M | 2025-12-31 | 2026-03-12 | 10-K | 26-017376 |
| 2 | assets | us-gaap:Assets | $499.8M | 2025-12-31 | 2026-03-12 | 10-K | 26-017376 |
| 3 | net income | us-gaap:NetIncomeLoss | -$9.5M | 2025-12-31 | 2026-03-12 | 10-K | 26-017376 |
| 4 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $37.5M | 2025-12-31 | 2026-03-12 | 10-K | 26-017376 |
| 5 | assets | us-gaap:Assets | $685.7M | 2024-12-31 | 2026-03-12 | 10-K | 26-017376 |
| 6 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $300.8M | 2025-12-31 | 2026-03-12 | 10-K | 26-017376 |
| 7 | gross profit | us-gaap:GrossProfit | $182.3M | 2024-12-31 | 2026-03-12 | 10-K | 26-017376 |
| 8 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $334.3M | 2024-12-31 | 2026-03-12 | 10-K | 26-017376 |
| 9 | gross profit | us-gaap:GrossProfit | $155.1M | 2023-12-31 | 2026-03-12 | 10-K | 26-017376 |
| 10 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $398.0M | 2023-12-31 | 2026-03-12 | 10-K | 26-017376 |
| 11 | gross profit | us-gaap:GrossProfit | $248.8M | 2022-12-31 | 2025-03-12 | 10-K | 25-012407 |
| 12 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $365.9M | 2022-12-31 | 2025-03-12 | 10-K | 25-012407 |
| 13 | gross profit | us-gaap:GrossProfit | $178.5M | 2021-12-31 | 2024-03-12 | 10-K | 24-010638 |
| 14 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $260.1M | 2021-12-31 | 2024-03-12 | 10-K | 24-010638 |
| 15 | current assets | us-gaap:AssetsCurrent | $309.5M | 2025-12-31 | 2026-03-12 | 10-K | 26-017376 |
| 16 | current liabilities | us-gaap:LiabilitiesCurrent | $186.3M | 2025-12-31 | 2026-03-12 | 10-K | 26-017376 |
| 17 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$517.5M | 2025-12-31 | 2026-03-12 | 10-K | 26-017376 |
| 18 | operating income | us-gaap:OperatingIncomeLoss | -$20.8M | 2025-12-31 | 2026-03-12 | 10-K | 26-017376 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 19 | book equity | us-gaap:StockholdersEquity | $61.1M | 2025-12-31 | 2026-03-12 | 10-K | 26-017376 |
| 20 | liabilities | us-gaap:Liabilities | $438.7M | 2025-12-31 | 2026-03-12 | 10-K | 26-017376 |
| 21 | operating income | us-gaap:OperatingIncomeLoss | -$130.9M | 2023-12-31 | 2026-03-12 | 10-K | 26-017376 |
| 22 | interest expense | us-gaap:InterestExpense | $13.6M | 2023-12-31 | 2024-03-12 | 10-K | 24-010638 |
| 23 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $303,000 | 2025-12-31 | 2026-03-12 | 10-K | 26-017376 |
| 24 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $16.1M | 2024-12-31 | 2026-03-12 | 10-K | 26-017376 |
| 25 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $756,000 | 2024-12-31 | 2026-03-12 | 10-K | 26-017376 |
| 26 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $21.8M | 2023-12-31 | 2026-03-12 | 10-K | 26-017376 |
| 27 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $3.8M | 2023-12-31 | 2026-03-12 | 10-K | 26-017376 |
| 28 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$106.6M | 2022-12-31 | 2025-03-12 | 10-K | 25-012407 |
| 29 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $10.8M | 2022-12-31 | 2025-03-12 | 10-K | 25-012407 |
| 30 | depreciation amortization | us-gaap:Depreciation | $3.8M | 2025-12-31 | 2026-03-12 | 10-K | 26-017376 |
| 31 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$5.9M | 2025-12-31 | 2026-03-12 | 10-K | 26-017376 |
| 32 | income tax | us-gaap:IncomeTaxExpenseBenefit | $3.6M | 2025-12-31 | 2026-03-12 | 10-K | 26-017376 |
| 33 | current assets | us-gaap:AssetsCurrent | $477.1M | 2024-12-31 | 2026-03-12 | 10-K | 26-017376 |
| 34 | current liabilities | us-gaap:LiabilitiesCurrent | $68.2M | 2024-12-31 | 2026-03-12 | 10-K | 26-017376 |
| 35 | assets | us-gaap:Assets | $929.1M | 2023-12-31 | 2025-03-12 | 10-K | 25-012407 |
| 36 | assets | us-gaap:Assets | $1.0B | 2022-12-31 | 2024-03-12 | 10-K | 24-010638 |
| 37 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 127,773,050 | 2026-03-09 | 2026-03-12 | 10-K | 26-017376 |
| 38 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 125,245,176 | 2025-03-10 | 2025-03-12 | 10-K | 25-012407 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.